If a Stock Market Crash Is Coming, History Shows This Stock Will Be a Brilliant Buy

Article argues J&J is positioned to outperform in a potential U.S. recession, citing its defensive healthcare exposure (pharma + medical devices), strong balance sheet (AAA credit rating), and dividend durability. It notes headwinds including Stelara patent cliffs, U.S. government drug price negotiations, and ongoing talc cancer lawsuits, but claims guidance supports healthy top-line growth into 2026. The piece highlights J&J’s 64-year dividend growth streak (Dividend King status) as a key income support.

Analysis

The market implication is not that JNJ becomes a high-conviction alpha long; it becomes a lower-volatility funding source and portfolio hedge if recession odds rise. In a slowdown, the incremental winner is not just the company itself but the broader defensive-healthcare sleeve (XLV/VHT) as allocators rotate away from consumer discretionary, small caps, and cyclicals. That rotation tends to happen before earnings weaken, so the better signal is macro deterioration plus a bid in defensives, not the article’s backward-looking recession framing.

The bigger second-order issue is that JNJ’s relative safety is already widely owned, which caps upside if the economy merely muddles through. If yields stay elevated and recession never arrives, the stock can lag higher-duration growth and quality cyclicals because the market will keep paying for earnings acceleration, not stability. The main company-specific overhang remains legal/regulatory headline risk; those are binary catalysts that can overwhelm a defensive multiple and should be treated as a discount-rate issue, not a recession issue.

From a timing perspective, the next 1-3 months matter most around macro prints and any healthcare pricing/litigation headlines. Over 6-18 months, the question is whether defensive cash flows deserve a premium when the Fed is still restrictive and healthcare policy risk is unresolved. The contrarian read: this is a fine portfolio ballast, but the article likely overstates stock-picking edge because most of the recession protection is already visible in the valuation and factor mix.

Key Decisions for Investors

• Do not chase JNJ after this type of defensive commentary; use it only on pullbacks versus XLV/VHT as a 3-6 month ballast position, with the thesis invalidated if JNJ underperforms XLV by >5% while recession data stays soft.
• Pair trade: long JNJ / short XLY for a 1-3 month recession-hedge expression. Best entry is after a hot CPI or weak payroll print when cyclicals sell off but healthcare has not yet re-rated; cut the trade if consumer-spend data reaccelerates and XLY recaptures relative strength.
• If the goal is lower-volatility income, prefer selling puts or using covered-call structures around JNJ only on volatility spikes tied to legal headlines; the risk/reward is better than outright chasing common stock at a full defensive multiple.
• Watch for a false recession signal: if 10Y yields move higher and credit spreads stay tight, rotate out of defensive exposure. That would favor trimming JNJ and adding back higher-beta healthcare names or cyclicals instead.
• Set an alert on litigation/regulatory developments and 2026 guidance revisions; any upward revision in reserve assumptions or margin pressure would be the clearest thesis breaker for a defensive-long stance.